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Goal of this study was to evaluate effects of Mao-to on development of myocarditis induced by
encephalomyocarditis (EMC) virus in mice. Mice were randomly divided into five groups.
Group N included uninfected controls (n=18), while group A, B and C underwent
intraperitoneal injection of EMC virus. Group A was administered oral saline from day 0 to
day 4. Group B was administered oral Mao-to (500mg
1kg
1day
1) from day 0 to day 4.
Group C was administered Mao-to from day 2 to day 6. Group D was administered Mao-to
from day 5 to day 10. Treated mice were followed for survival rates during 2 weeks after
infection. Body weight (BW) and organ weights including heart (HW), lungs, thymus and
spleen were examined on days 4, 6 and 14. Survival rate of group C (36.4%) was significantly
improved compared with group A, B or D (0% of each, P<0.05). HW and HW/BW ratio in
group C was significantly (P<0.05) lower than those in group A, B or D. Viral titers of hearts
were significantly different among groups A, B and C. Cardiac expression in tumor necrosis
factor-a (TNF-a) was significantly reduced in group C in comparison with group A, B or D on
day 6 by immunohistochemical study. Administration of Mao-to starting on day 2 improves
mortality resulting from viral myocarditis in mice with reduced expression of cardiac TNF-a.
These findings suggest that timing of Mao-to is crucial for preventing cardiac damage in mice
with viral myocarditis.
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Introduction
Myocarditis is an important cause of cardiomyopathy in
young patients (1). Therapeutics for myocarditis have
been restricted to supportive care including basic medi-
cations (2). Randomized trials of immunosuppressive
agents have failed to show a benefit (3). Immunomodu-
lative agents have been tried with limited effects (4). In
severe cases, heart transplantation presents the only
therapeutic option (1). Anti-inflammatory and anti-viral
agents are needed to improve outcomes in these patients.
Mao-to (Ma-Huang-tang in Chinese) is traditionally
used in Japan and China for treatment of influenza-like
illness (high fever, headache, pain and cough) since
ancient times. Component herb names (botanical names)
of Mao-to are as follows: Ephedra Herba (stem of
Ephedra Sinica Stapf), Cinnamomi Cortex (bark of
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properly cited.Cinnamomum cassia Blume), Armenicae Semen (semen of
Prunus Armeniacae Linne) and Glycyrrhizae Radix (root
of Glycyrrhizae uralensis Fisher) (5). Ephedra Herba was
reported to show the in vitro anti-influenza viral effects
and augments the production of inflammatory cytokines
including interleukin-6 and interleukin-1 (6,7). Moreover,
Cinnamomi Cortex, which contains Mao-to, suppress
IL-1a production in the influenza virus-infected mice
(8). Moreover, Mao-to has been studied for its anti-viral
and anti-autoimmune effects (9,10). Recently, anti-
pyrulent effect of Mao-to was reported in patients with
influenza infection (6). However, the effects of Mao-to in
viral myocarditis have not been studied. Inflammatory
cytokines are involved in the pathogenesis of myocardial
injury in viral myocarditis.
Tumor necrosis factor-a (TNF-a) is a proinflammatory
cytokine (11) that plays a crucial role in the initiation
and continuation of inflammation and immunity (12).
This cytokine has been implicated in the pathogenesis
of cardiovascular diseases, especially in viral myocarditis.
Our previous work showed that cardiac expression of
TNF-a mRNA is increased in a mouse model of viral
myocarditis (13). Over production of TNF-a is generally
considered to be harmful to the cardiovascular system,
because systemic administration of TNF-a results in
myocardial depression (14) and cardiomyopathy (15).
Cardiac-specific over-expression of TNF-a has been
reported to cause severe myocarditis in mice (16,17).
Therefore, we hypothesized that Mao-to would modify
viral myocarditis through anti-viral and anti-inflamma-
tory effects and that cardiac expression of TNF-a was
studied as an indicator of myocardial damages.
Methods
Mice
Eight-week-old C3H female mice (Charles River, Japan)
were used in the experiments.
Virus
A myocarditic variant of encephalomyocarditis (EMC)
virus was obtained from Y. Seto, Keio University,
Tokyo, Japan. Encephalomyocarditis virus was cultured
and purified followed by previous report (18). Animals
were inoculated intraperitoneally with 500 plaque-
forming units of EMC virus in 0.1ml of saline.
Chemicals
Mao-to which was supplied by Tsumura Co. (Tokyo,
Japan) was dissolved in distilled water, and diluted
with distilled water to the appropriate concentration.
HPLC finger print pattern of Mao-to is shown in Fig. 1.
Mao-to solution at the dose of 500mg
1kg
1 was
administered orally once daily to the mice. The dose of
Mao-to was based on the findings in previous reports
(19,20). The control mice were given saline.
Treatment Protocol
A total of 135 mice were assigned randomly to five
groups. Mice in groups B and C received Mao-to 10mg
per mouse in 0.1ml saline (500mg
1kg
1day
1) once
daily for 5 days. Group A was administered with 0.1ml
saline from day 0 to day 4. Group B was administered
with 0.1ml Mao-to from day 0 to day 4. Group C was
administered with 0.1ml Mao-to from day 2 to day 6.
Group D was administered 0.1ml Mao-to from day 5 to
day 10. Group N was the uninfected control group. The
survival rate of each group was monitored during the
observation period. Body weight and organ weight, and
histopathologic changes in the heart were examined on
day 4, 6 and 14 after infection.
Pathologic Examination
The heart and other organs were weighed. Body weight
(BW) also was recorded. One half of each organ was
fixed in 10% buffered formalin and stained with
hematoxylin-eosin; the other half was frozen in embed-
ding compound at 120C for immunohistochemical
studies. Transverse sections of ventricular myocardium
were graded for severity of necrosis and mononuclear cell
infiltration on a scale from 1 to 4 as follows: grade 1,
lesions involving <25% of the ventricular myocardium;
grade 2, lesions involving 25-50% of the myocardium;
grade 3, lesions involving 50-75% of the myocardium and
grade 4, lesions involving 75-100% of the myocardium.
Tissues were evaluated blindly by an experienced pathol-
ogist who was familiar with grading murine viral myo-
carditis and had no knowledge of the study design.
Measurements of Myofiber Diameter
In the lateral wall of the left ventricle, myocardial fiber
diameter was determined by measuring the shortest
diameter at the level of the nucleus of 50 myocardial
fibers from each group with an ocular micrometer in the
stained cross-sectional areas.
Immunohistochemical Examination
To visualize the presence and anatomic localization of
TNF-a within the myocardium, immunohistochemical
studies were performed using an avidin biotin complex
method (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA) as previously described (21). To minimize
thebackgroundstaining,allsectionswerefirstblockedwith
normal goat serum for 20min at room temperature.
342 Mao-to in myocarditisNext, the slides were incubated with an antibody directed
against murine TNF-a (Alpha-Diagnostic International
Inc., San Antonio, USA). Sections were counterstained
with hematoxylin and eosin. TNF-a immunostaining was
graded as follows: both nuclear and cytoplasmic staining 4;
strong cytoplasm staining 3; moderate cytoplasmic staining
2 and slight cytoplasmic staining 1.
Viral Titer in Heart
The EMC viral titer in the individual hearts was deter-
mined in terms of the viral cytopathic effects, and is
expressed as the tissue culture mean infectious dose
(TCID50). The hearts on day 4 after the inoculation
(n=3 of each group) were homogenized in 2ml of
MEM. After the centrifugation, the supernatants were
added into 96-well microtiter plates containing human
amnion cells in the MEM supplemented with 10% fetal
calf serum as described previously (21). The microtiter
plates were daily observed for 5 days to find the appear-
ance of any cytopathic effects.
Statistics
Data are reported as meansSD. The Kaplan–Meier
curves were generated to analyse differences in survival.
The differences in scores of myocardial damages were
examined by two-way analysis of variance to reveal the
combined effects of two different agents. Scheffes’ F-test
and Bonferroni/Dunn analysis were used for confirma-
tion. A level of P<0.05 was considered statistically
significant.
Results
Prolonged Survival
Survival rates on day 7 were 18.2% in group A, 18.2%
in group B, 63.6% in group C and 23.3% in group D.
The survival rates on day 14 were 0% in group A, 0% in
group B, 36.4% in group C and 0% in group D. The
survival rate in group C was significantly higher than
those in groups A, B or D (P<0.05, Fig. 2). Thus,
treatment with Mao-to starting on the day 2 after EMC
Figure 1. HPLC finger print pattern of Mao-to. HPLC conditions: Pulp: LC-10AD vp (Shimadzu, Japan); column: TSK-GEL ODS-80TS column
(2504.6mm; Tosoh, Japan); mobile phase: 0.05m AcONH4 (pH 3.6) (5).
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earlier or later was not effective in this regard.
Reduced Heart Weight
The results are shown in Fig. 3. The BW in group A and
B on day 6 after virus inoculation was significantly
(P<0.05) lower than that in group C. The HW/BW
ratio in group A on day 4 was elevated compared
with that of groups B and C (P<0.05). The HW and
HW/BW ratio in group C on day 6 after virus inocu-
lation was significantly (P<0.01) lower than that in
group A. Additionally, the HW/BW in group C on days
4 and 6 were significantly (P<0.01) lower than those in
group B. However, the HW and HW/BW ratio in group
C on days 4, 6 and 14 did not differ significantly from
those of the group N. In group D, HW and HW/BW
ratio on day 6 were significantly higher than those in
group N.
Decrease of Lung Congestion
The lung weight (LuW)/BW ratio on days 4 and 6 was
increased in groups A and B compared with group N.
The LuW/BW ratio on days 4 and 6 were significantly
reduced in group B and C vs. group A. In group C, the
LuW/BW ratio on day 4 was significantly lower than that
in group B, but that on day 6 was not significantly
different than group B. In group D, LuW/BW ratio on
day 6 was significantly higher than that in group N.
Reduction of Thymus Weight and Enlarged Spleen
The thymus weight (ThW)/BW ratio in groups A, B, C
and D on day 6 was significantly (P<0.05) lower than in
the group N and the spleen weight (SpW)/BW ratios in
groups A, B and C on days 4 and 6 were significantly
(P<0.05) higher than in group N (Fig. 4). Although the
ThW/BW ratio on day 6 in group C did not differ from
that in group A, the SpW in group C on day 6 was
significantly (P<0.05) higher than in groups N and A.
In group D, ThW/BW ratio on day 6 was significantly
lower than that in group N and SpW/BW was signif-
icantly higher than that in group N.
Decreased Myocardial Diameter and Myocardial Damage
The myocardial diameter was significantly smaller in
group C than that in group A and B on day 6, as shown
in Fig. 5. Myofiber diameter in group A was significantly
larger than that in group N. The scores of myocardial
necrosis and mononuclear cell infiltration were signifi-
cantly reduced in group C compared with groups A, B
and D on day 6 (Fig. 6A).
Suppression of Expression of TNF-a in Heart
Localized expression of TNF-a in the heart is shown in
Fig. 6B. Endothelial cells and myofiber were positive for
TNF-a in groups A and B on days 4 and 6. Myofibers
from group C were less positive than those from groups
A and B on day 6. The grading of TNF-a immunostain-
ing on day 6 was relatively lower in group C compared
with those in group A, B or D (P<0.05, n=3 of each,
Fig. 4). In addition, comparative expression of cardiac
TNF-a mRNA in the group C were significantly less than
in the groups A, B or D (Fig. 7).
Viral Titer in Heart
On day 4, viral titer in the hearts was not significantly
elevated in the Mao-to groups compared with that in the
group A (group B; 3.30.8 TCID/mg, group C; 3.00.7
TCID/mg vs. group A; 3.51.0 TCID/mg), although the
titer in group C was slightly lower than that in group A.
Discussion
At present, we have shown that Mao-to, administered
2 days after viral inoculation in C3H/HeJ mice, improves
survival rates, and reduces both myocardial necrosis and
mononuclear cell infiltration in mice with viral myocar-
ditis. Accordingly, SpW/BW ratios were elevated in these
mice. However, the administration of Mao-to at the same
time as virus inoculation did not influence survival
or myocardial destruction. We conclude that Mao-to
has an anti-viral effect on EMC viral myocarditis in this
mouse model in vivo and involves the modulation of early
immune responses with the reduction of cardiac TNF-a
Figure 2. Survival in mice after viral inoculation. survival was signifi-
cantly (P<0.01) improved in the group C as compared with mice in
groups A, B or D. Group A: administered with 0.1ml saline starting on
day 0 to day 6, group B: administered with 0.1ml Mao-to starting on
day 0 to day 4, group C: administered with 0.1ml Mao-to starting
on day 2 to day 6, group D: administered 0.1ml Mao-to from day 5 to
day 10.
344 Mao-to in myocarditismRNA, although the viral titer of hearts were not
significantly changed.
The LuW/BW ratio reflects the degree of lung
congestion. The two days later administration of Mao-
to and virus as group C leads to a significant reduction
in LuW/BW on day 6. The reduction of LuW/BW ratios
in group B are considered to reflect an improvement in
congestive heart failure due to viral myocarditis. The
effect of Mao-to on histopathological changes depends
on the timing of administration. As noted, when
administered two days following viral inoculation, Mao-
to led to significant reduction of myocardial necrosis and
mononuclear cell infiltration.
The reasons why oral administration of Mao-to was
started on 2 days after virus inoculation, should be
discussed. Our previous data showed that the both
peaks of serum TNF-a and interferon were identified
on day 2 after viral inoculation in this murine model (21).
Neutralizing antibody titer was confirmed on day 4.
Oral administration of Mao-to was effective in patients
Figure 3. Heart and lung weight in murine viral myocarditis. Heart weight, heart weight/bodyweight ratio and lung weight/body weight ratio on day
6 was significantly reduced in group C compared with group N. Abbreviations; N: uninfected control mice, A: administered with 0.1ml saline
starting on day 0 to day 6, B: administered with 0.1ml Mao-to starting on day 0 to day 4, C: administered with 0.1ml Mao-to starting on day 2 to
day 6. *P<0.05 vs. group N, P<0.05 vs. group A.
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Mao-to has been reported to show an in vitro anti-viral
effect (6). These reports suggest that the starting time of
administration, 2 days after virus inoculation, could
suppress these reactions instead of other days after virus
inoculation.
The reasons why Mao-to administration starting on
day 0 (group B) did not prolong the survival should be
discussed. It is known that Mao-to increase the blood
pressure, heart rate and cardiac output and decrease the
total peripheral resistance (22). From day 0 to 4, the
main course of viral myocarditis is the infection of viral
genome to myocytes, not the secondary immune cell
infiltration in the heart. Mao-to administration on day 0
to 4 is possible to make myocyte damages worse by
inducing excessive contraction of infected myocytes.
TNF-a is secreted primarily by myocytes and macro-
phages after injury (23). Elevation of TNF-a contributes
to the extent of ventricular dysfunction as shown in
TNF-a knockout mice (24). Previous studies have
demonstrated that cardiac-specific expression of TNF-a
results in myocardial inflammation, cardiac hypertrophy,
progressive dilatation and increased apoptosis, which
leads to heart failure and death (25). TNF-a may play
an important role in modulating left ventricular
dysfunction (26).
The present study also suggests that Mao-to may play
a role in cytokine regulation of host defense mechanisms
against viral myocarditis in mice in vivo. Comparative
studies on anti-immune effects of Mao-to were reported.
Mao-to prevents passive cutaneous anaphylaxis and also
inhibits histamine and leukotriene C4 release from the mast
cells (27). These suppressive effects may be due to the
interaction of its components such as Ephedra Herba and
Cassia Twig. The former was showed to suppress inter-
leukin-1 and 6 and the latter suppresses interleukin-1a
Figure 4. Thymus and spleen weight in murine viral myocarditis. Thymus weight in Mao-to-treated groups A, B, C and D were significantly reduced
compared with group N on day 6. Spleen weight/body weight ratio were significantly increased in group C compared with group N. Groups as are
described in Fig. 2. *P<0.05 vs. group N, P<0.05 vs. group A.
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host defense is well appreciated. The anti-viral mechanism
of Mao-to in mice may be to elicit these immune responses
and to enhance immune cell function rather than to directly
interfere with viral replication (10). Indeed, Mao-to was
reported to be effective in the suppression of hepatitis
virus in combination with interferon beta (6). Recently,
Cinnamomi Cortex, a component of Mao-to, was reported
to inhibit nuclear factor-kappa B (NF-kB) activation in
mice (28). NF-kB is the most regulator of the innate
immune response (29). Therefore, Mao-to might contribute
to the regulation of innate immunity in vivo.
An additional reflection of immunomodulation by
Mao-to was the enlargement of lymphoid organs, includ-
ing spleen in group C. Although the precise mechanisms
of Mao-to effect are not addressed by the examination of
organ weights, the increased SpW/BW and ThW/BW
ratios may be related to the immunomodulatory effect of
Mao-to (21,26).
In summary, oral administration of Mao-to two days
after inoculation is beneficial to mice infected with the
EMC virus and with subsequent active viral myocarditis.
The present study supports the observations that Mao-to
promotes temperately adaptive immune responses in
spleen and heart muscle, and the consequent attenuation
of viral replication when Mao-to is administered two
days after the virus inoculation. However, Mao-to treat-
ment must be concomitant with other treatment modal-
ities. It would be better to further clarify the potential
activities of Kampo medicine as well as Mao-to in
basic investigations or clinical trials (30-32). Additional
experiments are underway to explain specifically the
mechanism by which Mao-to protects against viral
myocarditis.
Figure 5. Myofiber diameter, cardiac histopathologic scores and grading of cardiac expression of TNF-a protein in murine viral myocarditis. Groups
as are described in Fig. 2. Grades of severity of necrosis and mononuclear cell infiltration on a scale from 1 to 4 are as follows: grade 1, lesions
involving <25% of the ventricular myocardium; grade 2, lesions involving 25-50% of the myocardium; grade 3, lesions involving 50-75% of the
myocardium; and grade 4, lesions involving 75-100% of the myocardium. ND; not determined, *P<0.05 vs. group N, P<0.05 vs. group A.
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